KYNTRA BIO, INC. Selling, General and Administrative Expense
KYNTRA BIO, INC. (KYNB) reported Selling, General and Administrative Expense of $9.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- KYNTRA BIO, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $9.27M, a 31.30% increase year-over-year.
- KYNTRA BIO, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $5.86M, a 27.68% decline year-over-year.
- KYNTRA BIO, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $7.25M, a 13.13% decline year-over-year.
- KYNTRA BIO, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $5.29M, a 43.44% decline year-over-year.
- KYNTRA BIO, INC. selling, general and administrative expense for fiscal 2025 was $27.71M, a 43.83% decline from fiscal 2024.
- KYNTRA BIO, INC. selling, general and administrative expense for fiscal 2024 was $49.33M, a 42.96% decline from fiscal 2023.
- KYNTRA BIO, INC. selling, general and administrative expense for fiscal 2023 was $86.48M, a 30.64% decline from fiscal 2022.
- KYNTRA BIO, INC. selling, general and administrative expense for fiscal 2022 was $124.69M, a 0.62% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.27M 10-Q · filed 2026-08-13 | $15.13M 10-Q · filed 2026-08-13 | $22.38M derived: sum of 3 quarters · filed 2026-08-13 | $27.67M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $5.86M 10-Q · filed 2026-05-12 | $13.11M derived: sum of 2 quarters · filed 2026-05-12 | $18.41M derived: sum of 3 quarters · filed 2026-05-12 | $25.46M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $12.54M derived: sum of 2 quarters · filed 2026-03-16 | $19.60M derived: sum of 3 quarters · filed 2026-08-13 | $27.71M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $5.29M 10-Q · filed 2025-11-10 | $12.35M derived: sum of 2 quarters · filed 2026-08-13 | $20.46M 10-Q · filed 2025-11-10 | $28.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $7.06M 10-Q · filed 2026-08-13 | $15.16M 10-Q · filed 2026-08-13 | $23.51M derived: sum of 3 quarters · filed 2026-08-13 | $32.87M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $8.11M 10-Q · filed 2026-05-12 | $16.45M derived: sum of 2 quarters · filed 2026-05-12 | $25.81M derived: sum of 3 quarters · filed 2026-05-12 | $40.72M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $8.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $17.71M derived: sum of 2 quarters · filed 2026-03-16 | $32.61M derived: sum of 3 quarters · filed 2026-03-16 | $49.33M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $9.36M 10-Q · filed 2025-11-10 | $17.55M 10-Q · filed 2024-11-12 | $24.27M derived: sum of 2 quarters · filed 2025-11-10 | $40.98M 10-Q · filed 2025-11-10 | $62.65M 10-Q · filed 2024-11-12 | $36.44M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $14.91M 10-Q · filed 2025-08-11 | $22.28M 10-Q · filed 2024-08-06 | $31.62M 10-Q · filed 2025-08-11 | $45.10M 10-Q · filed 2024-08-06 | $27.07M derived: sum of 3 quarters · filed 2025-08-11 | $52.65M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $16.71M 10-Q · filed 2025-05-12 | $22.82M 10-Q · filed 2024-05-06 | $12.17M derived: sum of 2 quarters · filed 2025-05-12 | $37.74M derived: sum of 3 quarters · filed 2025-05-12 | $68.92M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $21.03M derived: sum of 2 quarters · filed 2025-03-17 | $52.21M derived: sum of 3 quarters · filed 2025-03-17 | $86.48M 10-K · filed 2025-03-17 | $115.25M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $25.57M 10-Q · filed 2024-11-12 | $56.75M derived: sum of 2 quarters · filed 2024-11-12 | $91.03M 10-Q · filed 2024-11-12 | $125.00M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $31.18M 10-Q · filed 2024-08-06 | $65.45M 10-Q · filed 2024-08-06 | $99.42M derived: sum of 3 quarters · filed 2024-08-06 | $129.32M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $34.27M 10-Q · filed 2024-05-06 | $68.24M derived: sum of 2 quarters · filed 2024-05-06 | $98.14M derived: sum of 3 quarters · filed 2024-05-06 | $128.40M derived: sum of 4 quarters · filed 2024-05-06 | ||||
| 2022-12-31 | $33.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $63.87M derived: sum of 2 quarters · filed 2024-02-26 | $94.13M derived: sum of 3 quarters · filed 2024-02-26 | $124.69M 10-K · filed 2024-02-26 | ||||
| 2022-09-30 | $29.90M 10-Q · filed 2023-11-06 | $60.16M derived: sum of 2 quarters · filed 2023-11-06 | $90.72M 10-Q · filed 2023-11-06 | $125.46M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $30.26M 10-Q · filed 2023-08-07 | $60.82M 10-Q · filed 2023-08-07 | $95.56M derived: sum of 3 quarters · filed 2024-02-26 | $121.41M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $30.56M 10-Q · filed 2023-05-08 | $65.30M derived: sum of 2 quarters · filed 2024-02-26 | $91.16M derived: sum of 3 quarters · filed 2024-02-26 | $123.71M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $60.59M derived: sum of 2 quarters · filed 2024-02-26 | $93.15M derived: sum of 3 quarters · filed 2024-02-26 | $123.92M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $25.85M 10-Q · filed 2022-11-07 | $58.41M derived: sum of 2 quarters · filed 2022-11-07 | $89.19M 10-Q · filed 2021-11-09 | $131.44M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $32.55M 10-Q · filed 2022-08-08 | $63.33M 10-Q · filed 2021-08-09 | $105.58M derived: sum of 3 quarters · filed 2023-02-27 | $56.60M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $30.78M 10-Q · filed 2022-05-09 | $73.03M derived: sum of 2 quarters · filed 2023-02-27 | $24.05M derived: sum of 3 quarters · filed 2023-02-27 | $87.58M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $42.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$6.73M derived: sum of 2 quarters · filed 2023-02-27 | $56.80M derived: sum of 3 quarters · filed 2023-02-27 | $106.41M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | -$48.98M 10-Q · filed 2021-11-09 | $14.55M derived: sum of 2 quarters · filed 2021-11-09 | $64.16M 10-Q · filed 2021-11-09 | $114.86M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2020-06-30 | $63.53M 10-Q · filed 2021-08-09 | $113.14M 10-Q · filed 2021-08-09 | $163.84M derived: sum of 3 quarters · filed 2022-03-04 | $199.67M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2020-03-31 | $49.60M 10-Q · filed 2021-05-10 | $100.31M derived: sum of 2 quarters · filed 2022-03-04 | $136.13M derived: sum of 3 quarters · filed 2022-03-04 | $162.87M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2019-12-31 | $50.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-04 | $86.53M derived: sum of 2 quarters · filed 2022-03-04 | $113.27M derived: sum of 3 quarters · filed 2022-03-04 | $135.48M 10-K/A · filed 2022-03-04 | ||||
| 2019-09-30 | $35.82M 10-Q · filed 2020-11-05 | $62.56M derived: sum of 2 quarters · filed 2020-11-05 | $84.77M 10-Q · filed 2020-11-05 | $102.62M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $26.74M 10-Q · filed 2020-08-06 | $48.95M 10-Q · filed 2020-08-06 | $66.80M derived: sum of 3 quarters · filed 2021-03-01 | $82.16M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $22.21M 10-Q · filed 2020-05-07 | $40.06M derived: sum of 2 quarters · filed 2021-03-01 | $55.42M derived: sum of 3 quarters · filed 2021-03-01 | $70.47M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $17.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $33.21M derived: sum of 2 quarters · filed 2021-03-01 | $48.26M derived: sum of 3 quarters · filed 2021-03-01 | $63.81M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $15.36M 10-Q · filed 2019-11-12 | $30.41M derived: sum of 2 quarters · filed 2019-11-12 | $45.96M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $15.05M 10-Q · filed 2019-08-08 | $30.61M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $15.55M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $51.76M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |